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Background/aim: Colorectal cancer (CRC) is a major public health problem worldwide and in Tunisia due to its increasing rate of
incidence. KRAS and NRAS mutations have become a pivotal part of CRC diagnosis, given their association to treatment resistance
with antiepidermal growth factor receptor (EGFR) monoclonal antibodies. In this study, we aimed to screen for mutations in KRAS and
NRAS genes in Tunisian patients with CRC and explore their correlations with clinicopathological features.
Materials and methods: AmoyDx KRAS and NRAS mutation real-time PCR kits were used to screen for mutations in KRAS (exon 2)
and NRAS (exons 2, 3, and 4) in 96 CRC tumors.
Results: KRAS exon 2 mutations were found in 41.7% (40/96) of the patients. Codon 12’s most abundant mutations were G12D and
G12V, followed by G12A, while G13D is the predominant mutation in codon 13. KRAS exon 2 mutations were associated with older
patients (P = 0.029), left-sided tumors (P = 0.037), and greater differentiation (P = 0.044). The prevalence rate of NRAS mutations was
7.3%, mostly in exon 2. These mutations were associated with early stages of the disease (P = 0.039) and the absence of lymph node
metastasis (P = 0.045).
Conclusion: It can be inferred from this study that Tunisian CRC patients have a similar frequency of KRAS and NRAS mutations
compared to those observed in other populations. Consequently, screening for KRAS and NRAS mutations is crucial for the orientation
of therapies and the selection of appropriate candidates, while also helping to avoid unnecessary toxicity and increased costs for patients.
Key words: Sporadic colorectal cancer, KRAS, NRAS, real-time PCR, ARMS-PCR, Tunisia

1. Introduction
Due to its increasing incidence and mortality rates,
colorectal cancer (CRC) is a major global health concern
[1]. This neoplasm ranks as the 3rd most common cancer
among both men and women, with nearly 1.8 million new
diagnosed cases each year [1,2].
The 2018 Global Cancer Statistics ranked CRC as the
2nd leading cause of cancer-related morbidity, with an
estimated 881,000 cancer deaths worldwide [1].
As a public health problem worldwide and in Tunisia,
CRC incidence has increased over the past 20 years [3,4].
In Tunisia, colorectal carcinoma is considered to be the
most frequent digestive cancer [5,6].
The adenoma-carcinoma sequence is a multistep
process that starts with genetic alterations in early
adenoma, and accumulation transforms it into carcinoma
[7].

Studies pinpointed 3 major pathways that are
responsible for genomic instability in CRC: chromosomal
instability, microsatellite instability, and CpG island
methylator phenotype [8]. Most colorectal cancers arise
through the chromosomal instability pathway due to the
accumulation of somatic mutations in protooncogene
(KRAS) and tumor suppressor genes such as APC and
TP53 [8].
KRAS mutations are considered to be an early event in
tumorigenesis [8–11]. In colorectal cancer, approximately
30% to 50% of tumors harbor these mutations [11–13].
Approximately 90% of KRAS mutations are located
in codons 12 and 13 [11,14]. They are mostly singlenucleotide point mutations, particularly G>A transitions
and G>T transversions [15,16].
As a main effector molecule in the epidermal growth
factor receptor (EGFR) signaling pathway, mutant KRAS
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tumors exhibit resistance to EGFR-targeted therapies [17].
Subsequently, the American Society for Clinical Oncology
(ASCO) and the National Comprehensive Cancer Network
(NCCN) have recommended that KRAS gene mutation
analysis occur before anti-EGFR therapies [18,19].
In 2009, the US Food and Drug Administration (FDA)
and European Medicines Agency (EMEA) deemed the
2 EGFR antagonists, cetuximab and panitumumab, as
“not recommended” for the treatment of patients with
metastatic CRC (mCRC) harboring KRAS mutations
[16,20].
However, most patients with KRAS codons 12/13 wildtype colorectal cancer still fail to respond to anti-EGFR
therapy, suggesting the involvement of other mutations
[21,22].
In this context, NRAS, a member of the RAS family,
is found to be mutated in 1%–7% of colorectal cancers
[23]. In fact, recent research showcased that mutations in
KRAS exons 3 and 4 and NRAS gene exons 2, 3, and 4 are
associated with resistance to the anti-EGFR antibody or to
poor prognosis in mCRC [24,25]. Thus, EMEA and ASCO,
have made it mandatory to investigate exons 2, 3, and 4
of both KRAS and NRAS prior to the use of any novel
targeted therapies such as anti-EGFR treatments [2,26].
In conclusion, the RAS gene family (KRAS and NRAS)
status allows for the better the orientation of therapies
and, therefore, make it possible for patients to avoid
unnecessary toxicity and additional costs related to care
[8,16,22].
In view of these points, our work aims to screen
for mutations in KRAS and NRAS genes in Tunisian
patients with sporadic colorectal cancer and explore their
correlations with clinicopathological features.
2. Materials and methods
2.1. Patients and tumor samples
We conducted this retrospective study from 2010 to 2018
with the information from the cases of 96 sporadic CRC
patients. The study protocol was approved by the Ethics
Committee of Mongi Slim Hospital, La Marsa, Tunisia.
Mutational analyses were performed on frozen
specimens taken from patients who underwent colorectal
tumor resection at the Department of Surgery on archival
paraffin-embedded tissue blocks, either on primary or
metastatic samples and preserved at the Department of
Pathology and Cytology of the Mongi Slim Hospital, La
Marsa, Tunisia.
Clinicopathological features (age, sex, tumor location,
histological type, differentiation, depth of invasion,
TNM (tumor node metastasis) stage, and lymph node
metastasis were collected for each patient from surgical
and pathological records.

2.2. Samples selection and DNA extraction
After evaluating standard hematoxylin/eosin-stained slides
from primary and metastatic colorectal adenocarcinomas,
appropriate samples were specifically selected by a
pathologist to include predominately tumor cells without
significant necrosis or inflammation. Five 5.0-μm-thick
unstained sections were cut from the preselected paraffin
blocks; for the frozen specimens, 25 mg was taken from
each sample.
DNA was extracted using the PureLink Genomic DNA
Mini Kit (Invitrogen, Carlsbad, CA, USA), following the
manufacturer’s instructions.
DNA concentration was assessed using a Qubit dsDNA
HS (high sensitivity) Assay kit (ThermoFisher Scientific,
Waltham, MA, USA) on a Qubit 2.0 Fluorometer
(ThermoFisher Scientific), according to manufacturer’s
instructions.
2.3. Analysis of KRAS and NRAS gene mutations by
amplification-refractory mutation system-polymerase
chain reaction (ARMS-PCR)
The AmoyDx KRAS Seven Mutations Detection and NRAS
Mutations Detection kits (Amoy Diagnostics Co., Xiamen,
China) were used to detect the KRAS and NRAS status of
each DNA sample. Both kits are Chinese Food and Drug
Administration (CFDA) approved for clinical use in China
and marked for in vitro diagnostic (IVD) use in Europe by
the Conformité Européenne (CE)
These highly sensitive kits are based on a patented
technology ADxARMS, enabling the detection of 1%
mutant DNA in a background of 99% normal DNA in a 10ng DNA sample, while ensuring minimal false negatives.
The AmoyDx KRAS Seven Mutations Detection Kit
is designed to accurately identify the 7 most common
activating KRAS mutations in codons 12 and 13 (Table 1).
The AmoyDx NRAS Mutation Detection Kit is intended
to meticulously detect 16 hotspot somatic mutations
in codons 12, 13, 59, 61, 117, and 146 of the NRAS gene
(Table 1).
The extracted DNA quality was evaluated by amplifying
a housekeeping gene and using the HEX channel provided
with the kit.
PCR reactions were performed using a Stratagene
Mx3005P (Agilent Technologies, Inc., Santa Clara, CA,
USA) under the following conditions: 5 min incubation at
95 °C, followed by 15 cycles of 95 °C for 25 s, 64 °C for 20
s, 72 °C for 20 s, and then 31 cycles of 93 °C for 25 s, 60 °C
for 35 s, and 72 °C for 20 s.
The fluorescent signal was collected from the FAM and
HEX channels. It is important to note that every PCR run
must contain one PC (positive control) and one NTC (no
template control). KRAS and NRAS mutation status was
determined according to the Ct value as indicated in the
manufacturer’s instructions.
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Table 1. KRAS and NRAS Mutations detected with the AmoyDx kit.
Gene

KRAS

Exon

2

Codon

12

13

12
2

13
NRAS

59
3

4

61

117
146

Mutation

Base change

Cosmic ID

G12C

34G>T

516

G12S

34G>A

517

G12R

34G>C

518

G12V

35G>T

520

G12D

35G>A

521

G12A

35G>C

522

G13D

38G>A

532

G12C

34G>T

562

G12S

34G>A

563

G12D

35G>A

564

G12A

35G>C

565

G12V

35G>T

566

G13R

37G>C

569

G13D

38G>A

573

G13V

38G>T

574

A59D

176C>A

253327

Q61K

181C>A

580

Q61L

182A>T

583

Q61R

182A>G

584

Q61H

183A>C

586

K117N

351G>C

_

K117N

351G>T

_

A146T

436G>A

27174

2.4. Statistical analysis
All statistical analyses were performed using SPSS software,
version 20 (SPSS, Inc., Chicago, IL, USA). Associations
between variables were tested with the chi-square (χ2) test.
A probability (P) value of less than 0.05 was considered to
be statistically significant.
3. Results
3.1. Patient and tumor characteristics
In our 96 CRC patients, CRC prevalence was higher in
males (62.5%, 60/96) than in females (37.5%, 36/96). The
mean age of the Tunisian patients, at tumor resection, was
62.4 years old, ranging from 23 to 92 years of age.
Regarding the histological subtypes of our series,
69.8% (67/96) of tumors were nonmucinous (NMC), and
30.2% (29/96) were mucinous adenocarcinomas (MC).
The tumors were graded according to the WHO
criteria (World Human Organization Classification of
Tumours of the Digestive System, 4th Edition) [27] as
follows: 47 (49%) were well-differentiated, 46 (47.9%)
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were moderately differentiated, and 3 (3.1%) were poorly
differentiated.
A total of 71 samples (73.96%) were located in the left
colon and 25 (26.04%) in the right colon.
Histologic classification of tumors was made according
to the international TNM staging system based on the
8th edition of the American Joint Committee on Cancer
(AJCC; 8th edition) [28].
Specimens were taken from 70 primary tumors
(72.92%) and 26 metastasis (27.08%), distributed between
32 cases in the primary stage (stages I and II) and 64 cases
in the advanced stage (stages III and IV).
3.2. Distribution of KRAS and NRAS mutations in
colorectal carcinomas
The distribution of KRAS and NRAS mutations in the 96
CRC patient samples is presented in Table 2.
KRAS exon 2 mutations were observed in 41.7%
(40/96) of the cases, and 7 cases had 2 concomitant
mutations. Therefore, in a total of 40 cases, we had 47
mutations in KRAS exon 2, distributed as follows: 40 (85%)
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Table 2. Distribution of KRAS and NRAS mutations in the 96 CRC patient samples.
Gene

Exon

Codon

Mutation

Numbers of mutations
(% of 96)

KRAS

2

12,13

G12D, G12A, G12V, G12S, G12R, G12C, G13D

47 (48.96)

NRAS

2

12,13

G12D, G12S,G13D, G13R, G12C, G12V, G12A, G13V

5 (5.21)

NRAS

3

59,61

A59D, Q61R, Q61K, Q61L, Q61H

3 (3.12)

NRAS

4

117,146

K117N, A146T

0

were detected in codon 12, and 7 (15%) were identified in
codon 13.
The most prevalent mutations were G12D and G12V at
25.5% (12/47) each, followed by G12A at 17% (8/47); then
G13D at 14.9% (7/47), G12R and G12C at 6.4% (3/47)
each, and G12S at 4.3% (2/47).
Mutations outside KRAS exon 2 were observed in the
NRAS gene in 7.3% (7/96) of the cases. One case showed
2 NRAS mutations. These 8 mutations were distributed as
follows: 62.5% (5/8) in exon 2 (codons 12 or 13); 37.5%
(3/8) in exon 3 (codon 61); and none in exon 4 (codon
146).
Figure displays the different mutation profiles, shown
in subfigures (a), (b), and (c).
In our study, none of the patients harbored a
simultaneous mutation in KRAS (exon 2) and NRAS
(exons 2, 3, and 4). Therefore, these mutations were
mutually exclusive.
3.3. Association between KRAS/NRAS mutations and
clinicopathological features
A summary of the relationships between KRAS and NRAS
mutations and various clinicopathological features is
provided in Table 3.
KRAS mutations were much higher in older patients
(>60 years old) (80% vs. 20%, P = 0.029) and were
significantly more prevalent in the left side of the colon
than on the right side (85% vs. 15%, respectively; P =
0.037). Meanwhile, these mutations were significantly
associated with well-differentiated tumors but less with
moderately and poorly differentiated tumors (62.5% vs.
37.5% vs. 0%, respectively; P = 0.044).
Although KRAS mutation frequency is higher in NMC
(80%), the difference is not statistically significant (P =
0.066).
There was no significant relationship between KRAS
mutations and sex (P = 0.669), lymph node metastasis (P
= 0.446), or tumor stage (P = 0.884).
NRAS mutations were more frequent in stages I and II
(71.4%), compared with stage III and IV cancers (28, 6%)
(P = 0.039) and were associated with the absence of lymph
node metastasis N0 (P = 0.045).
However, no significant relationship was observed
between NRAS mutations and sex (P = 0.184), age (P =

0.149), tumor location (P = 0.260), histological type (P =
0.120), or tumor differentiation (P = 0.151).
4. Discussion
As the 3rd most common cancer among men and women,
CRC has increased in terms of incidence and mortality
worldwide and in Tunisia [1,3]. The 2018 Global Cancer
Statistics ranked CRC as the 2nd leading cause of cancerrelated morbidity, with an estimated 881,000 cancer deaths
worldwide and nearly 1.8 million newly diagnosed cases
each year [1,5,6].
It has been widely established that the KRAS mutation
pattern has a significant impact on the orientation of
anticancer therapy. In this context, tumors harboring exon
2 KRAS mutations (codons 12 and 13) do not benefit from
EGFR targeted therapies.
Interestingly, some wild-type KRAS exon 2 patients
did not respond well to anti-EGFR therapy, proving
that additional RAS mutations (KRAS exons 3 and 4
or NRAS exons 2, 3, and 4) can negatively predict the
success of anti-EGFR treatment.
In the present study, the frequencies of KRAS and NRAS
gene mutations were determined in Tunisian patients with
sporadic CRC. Additionally, we investigated correlations
between these genetic mutations and clinicopathological
features. Our results are consistent with previous studies in
which 50% of colorectal cancers harbored a RAS mutation
[29].
With a KRAS exon 2 mutation frequency of 41.7%, we
were in accordance with Tunisian and worldwide studies in
which frequencies ranged from 15% to 46%, respectively,
[30–33] and from 30% to 50% (Table 4).
Therefore, we noticed that KRAS mutations arise
at similar frequencies in Tunisian patients as in other
populations, and this may be attributed to the involvement
of the same genes in sporadic colorectal carcinomas,
regardless of the variation imposed by ethnicity,
geographical distribution, dietary, lifestyle factors, and
sensitivity to the different techniques used in previous
studies.
In accordance with previous reports, 90% of KRAS
mutations found in our cohort were located in codons
12 and 13. The majority occurred in codon 12 (85%) and
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Figure. Amplification plots of: (a) wild-type sample; (b) sample with one mutation; (c) sample with 2 mutations.

(15%) in codon 13. The most frequently observed types
of mutations were G>A transitions and G>T transversions
[14,16,31,34–36].
We found that the most abundant mutations of codon
12 were G12D and G12V, while G13D is the predominant
mutation in codon 13. These results are concordant with
local Tunisian studies [30,31,33,37] and international ones
[12,34,36,38–41].
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Similar to the data in the literature, we also report a
cluster of 4 mutation types (G12D, G12V, G12A, and
G13D), which account for 84.8% (39/46) of KRAS exon 2
mutations [38,39,41].
Correlations between KRAS and NRAS mutational
status and the different clinicopathological features are
very controversial. Some previous reports pinpointed that
the frequency of KRAS and NRAS mutation was associated
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Figure. (Continued).

with various clinicopathological criteria, but others did
not.
Regarding KRAS exon 2, most of our results were
consistent with the literature, notably the association with
age, tumor location, and histology.
Our data showed that KRAS exon 2 mutations seemed
to occur frequently in elderly patients. This result was
supported by many other studies [20,41–43].
When it comes to tumor location, disparities have been
reported where KRAS mutation rates were higher in the
right-sided CRC tumors [2,36,40,44]. Our study, along
with others, showed an association with the left side of the
colon rather than the right [45–48].
The cause of the divergent findings between left- and
right-side colon adenocarcinoma is still unclear [40]. It
could be attributed to the complex origin and the exposure
of left-sided luminal microenvironment to ingested
carcinogens and mutagens [40].
Our data align with those reported in the literature
that found that KRAS mutations showed a significant
association with well-differentiated tumors but less
with moderately differentiated tumors, with no or few
KRAS mutations found in poorly differentiated tumors
[2,29,31,35,36,46,48].
The association between KRAS mutations and
mucinous histotype was reported in some studies
[36,46,49] but denied in others [29,50,51], including ours.
Unlike KRAS mutations that are strongly implicated in
colorectal cancer, NRAS alterations are rare and, to date,

limited data on their mutation prevalence are available
[36].
In our study, the NRAS mutation rate was 7.3%, similar
to the only available Tunisian study, which reported 6.9%
[37].
Our data shows that 12.5% of wild-type KRAS exon
2 patients carried a mutation in NRAS exons 2 and 3.
Furthermore, recent data showed that 12%–17% of
patients with wild-type KRAS exon 2 (codons 12/13)
harbor a mutation in KRAS exons 3 and 4 and NRAS exons
2, 3, and 4 [25,52].
We observed that NRAS mutation incidence rates
varied depending on the population, whereas Zhang
reported a rate of 3.69% in a Chinese study [49], and 6%
and 6.3% frequencies were described in Italian and Indian
studies, respectively, [52,53] versus 9.57% in Greek and
Romanian patients [22].
In our study, NRAS mutations were associated with
early stages of cancer and the absence of lymph node
metastasis.
Some studies have observed that NRAS mutations
tended to occur in left-sided cancers and in women [54],
while Russo et al. reported associations with rectal cancer
and with patients 56 years or older [55].
Chang noted a correlation with the male sex [12].
Furthermore, Shen observed that these mutations were
more frequent in distant metastasis tumors, and its rate
varied with the different tumor stages [39]. Other studies
did not find any correlations [29,36,37,49].
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Table 3. Correlation between KRAS/ NRAS mutations and clinicopathological features.
KRAS status
Clinicopathological features

NRAS status

Number

Wild type
N = 56 (%)

Mutant type
N = 40 (%)

≥60 (n = 65)

65

33 (58.9)

32 (80)

<60 (n = 31)

31

23 (41.1)

8 (20)

Male (n = 60)

60

36 (64.3)

24 (60)

Female (n = 36)

36

20 (35.7)

16 (40)

Right colon (n = 25)

25

19 (33.9)

6 (15)

Left colon (n = 71)

71

37 (66.1)

34 (85)

NMC (n = 67)

67

35 (62.5)

32 (80)

MC (n = 29)

29

21 (37.5)

8 (20)

Well (n = 47)

47

22 (39.3)

25 (62.5)

Moderate (n = 46)

46

31 (55.4)

15 (37.5)

Poor (n = 3)

3

3 (5.3)

0 (0)

I, II (n = 32)

32

19 (33.9)

13 (32.5)

II, IV (n = 64)

64

37 (66.1)

27 (67.5)

No (n = 33)

33

21 (37.5)

12 (30)

Yes (n = 63)

63

35 (62.5)

28 (70)

P-value

Wild type
N = 89 (%)

Mutant type
N = 7 (%)

62 (69.7)

3 (42.9)

27 (30.3)

4 (57.1)

54 (60.7)

6 (85.7)

35 (39.3)

1 (14.3)

22 (24.7)

3 (42.9)

67 (75.3)

4 (57.1)

64 (71.9)

3 (42.9)

25 (28.1)

4 (57.1)

45 (50.6)

2 (28.6)

42 (47.2)

4 (57.1)

2 (2.2)

1 (14.3)

27 (30.3)

5 (71.4)

62 (69.7)

2 (28.6)

28 (31.5)

5 (71.4)

61(68.5)

2 (28.6)

P-value

Age (years)
0.029

0.149

Sex
0.669

0.184

Tumor location
0.037

0.260

Histological type
0.066

0.120

Differentiation
0.044

0.151

Stages
0.884

0.039

Lymph node metastasis

This divergence may be attributed to diverse ethnicities,
genetic factors, geographical distributions, and diagnostic
techniques.
Nowadays, various techniques for assessing RAS
mutation status are available, such as Sanger sequencing,
high-resolution melt analysis, pyrosequencing, and nextgeneration sequencing techniques [56]. Though the tests
vary in terms of sensitivity and specificity, no standard
method has yet been endorsed for clinical practice [57].
In our study, we used the AmoyDx Mutation Detection
Kit, a relatively simple real-time PCR assay that is fast and
less prone to external contamination [58]. It is considered
to be one of the most sensitive methods available in clinical
molecular laboratories [59].
Due to its high sensitivity and accuracy, the AmoyDx
KRAS real-time PCR kit has significantly higher mutation
detection rates than Sanger DNA sequencing [58].
Therefore, AmoyDx real-time PCR is an effective and
reliable tool for the clinical screening of somatic gene
mutations in colorectal tumors [58].
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0.446

0.045

However, we have to point out here that the present
study was retrospective with a small sample size and
focused only on KRAS exon 2 and NRAS exons 2, 3, and
4, preventing us from drawing any firm conclusions. Our
database did not include any detailed information about
adjuvant chemotherapy; hence, the patients’ adjuvant
treatment was not analyzed in the current study.
5. Conclusion
In conclusion, we studied mutations of KRAS and NRAS
genes in Tunisian CRC patients and their correlations with
clinicopathological features. Our results show that in terms
of incidence, KRAS and NRAS mutations occur at similar
frequencies in Tunisian patients as in other populations.
Meanwhile, clinicopathological features analysis showed
both similarities and differences when contrasted to those
reported in other studies.
Consistent with the literature, KRAS exon 2 was
associated with older patients, left-sided tumors, and
greater differentiation. Otherwise, no association was
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Table 4. KRAS mutation frequencies in different countries.
Country

KRAS mutation frequency

Reference

Australia

41.6%
47.2%
42.56%
39.6%
41.3%
35.7%
50%
39.2%
36.2%

[17]
[21]
[49]
[29]
[22]
[53]
[52]
[22]
[44]

China
France
Greece
India
Italy
Romania
USA

found with other clinicopathological criteria such as sex,
lymph node metastasis, tumor stage, or histological type.
In terms of NRAS mutations, our study showed an
association with early stages of cancer and the absence of
lymph node metastasis, different from various research
studies that reported an association with other features
like tumor location, sex, or age.

Therefore, screening for KRAS and NRAS mutation is
crucial in guiding therapies and the selection of appropriate
candidates, and in preventing unnecessary toxicity and
costs for patients.
Given the importance of such molecular analysis, future
studies can focus on the evaluation of other biomarkers
suggested as having poor or no benefit from anti-EGFR
therapy, such as KRAS exons 3 or 4, or BRAF.
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